Sobre o FUTURO
Tudo começou quando eu tinha por volta de 4 – 5 anos e após um acidente domiciliar, precisei passar por uma cirurgia na mão. A forma como aquele profissional que nos atendeu acalmou a angústia dos meus pais e tratou com habilidade o ferimento me marcou profundamente. Apesar de não ter ideia do que isso significaria na minha jornada futura, aquele sentimento de ação e resolução se tornou uma paixão que me acompanha até hoje.
Subtotal cholecystectomy for difficult acute cholecystitis
Laparoscopic cholecystectomy is considered the gold standard for treatment of benign gallbladder diseases. Cholecystectomy using this method can be completed in 90% of elective cholecystectomies and 70% of emergency cholecystectomies. Acute cholecystitis, especially if difficult, can change the above paradigm, resulting in open conversion or change of technique. The conditions that define a difficult cholecystectomy are as follows: necessity of conversion from laparoscopic to open surgery; duration of procedure greater than 180 min; blood loss greater than 300 ml; and urgent need for involvement of a more experienced surgeon. One of the “rescue” procedures to complete the surgery safely (both for the surgeons and patients) is subtotal cholecystectomy (STC). Open and laparoscopic subtotal cholecystectomy have been reported. For many surgeons, this is considered a bail out technique, and the timing of decision making is crucial to avoid catastrophic complications. Te capability to perform STC in laparoscopy is increasingly requested during difficult laparoscopic cholecystectomy. Difficult LC has a risk of BDI from 3 to 5 times higher in laparoscopy than open surgery. In case of operative difficulties of young surgeons mostly trained in laparoscopy the help of senior surgeons is strongly recommended. The purpose of the present study is to clarify how laparoscopic subtotal cholecystectomy may be used to complete a difficult cholecystectomy for acute cholecystitis without serious complications.
Biliary leakage represents the most frequent complication of incomplete resection of the gallbladder wall in cases of difficult acute cholecystectomy treated with subtotal cholecystectomy. This complication is rarely fatal but requires correct treatment. If bile leakage does not stop spontaneously seven days postoperatively, the possible treatments are endoscopic biliary sphincterotomy, endoscopic plastic stent, and a fully covered self-expanding metal stent. When performing closure of the gallbladder stump, suturing the anterior residual of both anterior and posterior wall represents the best method to have fewer complications. Complications, if not lethal, decrease the patient’s quality of life. Intraoperatively, it is of utmost importance to carefully expose the gallbladder stump to avoid left-in-place stones, wash the entire cavity and drain the abdomen. Bile duct injuries can be a significant complication in this type of surgery. Prevention of the lesions with conversion from laparoscopic to open, or the opinion of older surgeon in case of difficulties is strongly recommended. Mortality is a very rare complication. The limitations of our study are given by the heterogeneity of the techniques used for LSC and the lack of a long-term follow-up analyzing the related complications.
Liver Disease and Perioperative Risk
The liver is the biggest intestinal organ and plays a central role in the homeostasis of different physiological systems including nutrition and drug metabolism, the synthesis of plasma proteins and haemostatic factors, as well as the elimination of different endogenous and exogenous substances. Although the liver contributes with only 3% to total body weight, given its major role in homeostasis and high energy consumption, it receives 25% of total cardiac output (CO). Two vessels contribute to the perfusion of the liver. The majority (70%) of the hepatic perfusion is provided by the portal vein, which contributes 50% of the organ’s oxygen demand. The other 50% is provided by the hepatic artery, which makes up around 30% of total liver perfusion. Hepatic arterial blood flow is mainly dependent on the organ’s metabolic demands and controlled via autoregulatory mechanisms, whereas blood supply through the portal vein depends on the perfusion throughout the whole gastrointestinal tract and the spleen. This unique, dual perfusion system provides constant perfusion rates and oxygen supply, which is crucial for adequate liver function. These high oxygen demands are reflected in a hepatic vein saturation of almost 30%.
The liver is also unique in its ability of regeneration, which allows the performance of major surgery including, amongst others, extended resections of liver tumours, living donations and so on. Many patients have normal liver function parameters when they present for liver surgery, especially when the reason for resection is metastasis or a benign liver tumour. The most common causes of liver resections are the hepatocellular carcinoma (HCC) and the cholangiocellular carcinoma (CCC). Hepatocellular carcinoma (HCC) often develops in patients with underlying liver cirrhosis; many of these patients show signs of chronic liver dysfunction (CLD).
As explained previously, the liver plays a central role in a great deal of physiological systems. Therefore, in case of chronic liver dysfunction (CLD) or liver failure, several effects on other organ systems have to be expected. Consequently liver resections and bile duct surgery as having a high risk for perioperative cardiac events, with an estimated 30-day cardiac event rate (cardiac death and myocardial infarction) of more than 5%. Patients undergoing liver surgery pose a significant challenge to treating physicians in the perioperative period. Due to the improvement of surgical techniques, the “liver patient” is becoming more and more complex, confronting surgeons, anaesthetists and intensive care personnel with difficult intra- and postoperative courses, and considerable multiorgan disorders. The cornerstones of an optimal management are careful selection of the patients, appropriate monitoring and protection of the liver and other vital organs.
Surgical Management of PANCREATIC CANCER
Pancreatic ductal adenocarcinoma (PDAC) carries one of the poorest overall prognosis of all human malignancies. The 5-year survival in patients with PDAC, for all stages, remains as low as 6–7%. The low survival rate is attributed to several factors, of which the two most important are aggressive tumor biology and late stage at which most patients are diagnosed. Only 10–20% of patients are eligible for resection at presentation, 30–40% are unresectable/locally advanced, and 50–60% are metastatic. Pancreatic cancer without distant metastasis can be divided into three categories: resectable, borderline resectable, and locally advanced. In absence of metastatic disease, the most important factor for improving survival and possibly offer cure is to achieve a margin-negative resection. Even after potential curative resection, most patients develop recurrences eventually, and 5-year survival of completely resected patients is only up to 25%. The aggressive tumor biology and its inherent resistance to chemotherapy and radiotherapy contributes to early recurrence and metastasis.
Pancreatic cancer surgery has evolved over the past few decades and remains the cornerstone of treatment of resectable and borderline resectable tumors. Advances in modern imaging give precise information on disease extension and vascular involvement that aids in surgical planning in order to achieve a margin-negative resection.
Surgical techniques for pancreatic cancer include pancreaticoduodenectomy, distal pancreatectomy with splenectomy, and total pancreatectomy. Standard lymphadenectomy for pancreatoduodenectomy should include removal of lymph node stations 5, 6, 8a, 12b1, 12b2, 12c, 13a, 13b, 14a, 14b, 17a, and 17b. Involvement of superior mesenteric vein (SMV)/portal vein(PV) was previously considered as a contraindication for resection. However, curative resection along with SMV/PV with vascular reconstruction has now become a standard practice in specialized high-volume centers. To improve margin-negative resections, specially in borderline resectable tumors with proximity to vascular structures, SMA first approach was proposed as a new modification of standard pancreatico-duodenectomy. In a systematic review, SMA first approach was shown to be associated with better perioperative outcomes, such as blood loss, transfusion requirements, pancreatic fistula, delayed gastric emptying, and reduced local and metastatic recurrence rates. In case of arterial involvement, there is no good evidence at present to justify arterial resections for right-sided pancreatic tumors. However, the modified Appleby procedure, which includes en bloc removal of celiac axis with or without arterial reconstruction, when used in appropriately selected patients, offers margin negative resection with survival benefit for locally advanced pancreatic body and tail tumors and should be performed in high-volume centers. Most evidence does not support advantage of more extended resections such as removal of the para-aortic lymph nodes and nerve plexus and multivisceral resections routinely. Such extended resections are associated with compromised quality of life because of associated higher perioperative morbidity and intractable diarrhea. However, in highly selected patients, with preserved performance status and stable or nonprogressive disease on neoadjuvant treatment, such extended resections can provide survival advantage over palliative treatments. Radical surgery in the presence of oligometastatic disease has also been reported to prolong survival in highly selected patients.
Surgical Management of CHOLANGIOCARCINOMA
Cholangiocarcinoma is an uncommon cancer that occurs within the intrahepatic and extrahepatic portions of the bile duct system. In North America, the incidence of extrahepatic cholangiocarcinoma is 0.5–2 per 100,000 and 0.95 per 100,000 for intrahepatic cholangiocarcinoma. Up to 50% of patients will be lymph node (LN) positive at presentation, 5% are multifocal tumors, and 10–20% will have peritoneal involvement at presentation. Risk factors for cholangiocarcinoma are primary sclerosing cholangitis (PSC) with a lifetime risk 10–40%, parasitic infection, previous sphincteroplasty, congenital anomalies of the biliary tree (choledochal cyst, Caroli’s disease, anomalous pancreaticobiliary duct junction), and chronic biliary inflammatory disease (hepatitis B/C, liver cirrhosis, recurrent pyogenic cholangitis). The most common presentation is painless jaundice and weight loss in the setting of extrahepatic duct involvement. In Western countries, 80% are extrahepatic (20% distal and 60% hilar) and 20% are intrahepatic.
SPECIAL NOTESClick here and share on TWITTER
• Ca 19–9 can be elevated in up to 85% of patients with cholangiocarcinoma, but is not specific; elevation can also occur in the setting of obstructive jaundice without malignancy. If it remains elevated after biliary decompression, it could indicate the presence of malignancy. Elevated pre- and postoperative Ca 19–9 predict poor survival.
• For perihilar tumors, decisions regarding which side of the liver to resect depend on right- or left-sided dominance, volume of future liver remnant, and the extent of vascular and ductal involvement.
• Some centers report that 30–50% of tumors will be deemed unresectable at the time of surgery, despite accurate preoperative imaging.
• Quality Indicators: Pathologic Analysis—R0 margin, regional lymphadenectomy includes three or more LN.
Intrahepatic cholangiocarcinoma: Surgical resection is the only potential cure with removal of involved liver segments. There is emerging evidence that recommends a routine hilar LN and dissection for its prognostic value, M1 disease includes involvement of celiac,periaortic or caval LN.
Distal bile duct (below the cystic duct): Surgical resection is the only potential cure. Pancreaticoduodenectomy including en bloc resection of extrahepatic bile duct and gallbladder. Regional nodes include: Hilar (CBD, common hepatic, portal, cystic), Posterior and anterior pancreaticoduodenal Nodes along SMV, Nodes along right and lateral wall of SMA.
Hilar (above the cystic duct): En bloc resection of extrahepatic bile duct and gallbladder, including right and left hepatectomy, or extended right/left hepatectomy, Caudate lobe should be removed. Regional nodes include: Hilar (CBD, hepatic,portal, cystic), Pericholedochal nodes in hepatoduodenal ligament.
Preoperative Biliary Drainage
The most common presenting sign for patients with malignancy of the periampullary region is obstructive jaundice. While a significant proportion of these patients will be asymptomatic, the deleterious systemic consequences of uncontrolled hyperbilirubinemia may still occur. Furthermore, symptoms such as pruritus can be debilitating and have a significant impact on the quality of life. Thus, some have advocated preoperative drainage of the biliary system in patients with resectable periampullary malignancies, given widespread availability of endoscopic retrograde cholangiopancreatography and its perceived safety profile. On the other hand, the purported benefits of routine preoperative drainage in this patient population (namely, resolution of symptoms in symptomatic patients while awaiting surgery, restoration of the enterohepatic cycle, and a potential decrease in postoperative morbidity) have proven to be largely theoretical, and now there are high-quality phase III data that demonstrate the deleterious effects of routine stenting. A seminal study originating from the Netherlands in 2010 evaluated this issue in the only modern randomized controlled trial to date evaluating preoperative endoscopic biliary decompression for these patients. In their multicenter study, they randomized 202 patients with newly diagnosed pancreatic head cancer and bilirubin levels between 2.3 and 14.6 mg/dL to preoperative biliary drainage for 4–6 weeks vs. immediate surgery which was to be performed within a week of enrollment. The primary endpoint was the development of serious complications within 120 days after randomization. Serious complications were defined as complications related to the drainage procedure or the surgical intervention that required additional medical, endoscopic, or surgical management, and that resulted in prolongation of the hospital stay, readmission to the hospital, or death. The reported overall rate of serious complications in this study favored the immediate surgery group (39 vs. 74%; RR 0.54–95% [CI], 0.41–0.71; P < 0.001), complications related to surgery were equivalent (37 vs. 47%; P = 0.14), and there was no difference in mortality rates or length of hospital stay. The observed drainage-related complications included a 15% rate of stent occlusion, 30% need for exchange, and 26% incidence of cholangitis.
“Based on these results, the authors concluded that the morbidity associated with the drainage procedure itself had an additive effect on the postoperative morbidity of patients undergoing pancreatic head resection for cancer and recommended against its routine use in this population.“
A Cochrane systematic review of all available randomized studies (including the abovementioned study by van der Gaag et al.) evaluating preoperative biliary drainage was published in 2012. In this study, Fang et al. assessed the impact of this intervention on survival, serious morbidity (defined as Clavien-Dindo grade 3 or 4), and quality of life. Furthermore, they sought to assess differences in total length of hospital stay and cost. They identified six randomized trials of which four used percutaneous transhepatic biliary drainage and the remaining two used endoscopic sphincterotomy and stenting. The pooled analysis of 520 patients (of which 51% underwent preoperative biliary drainage) showed no difference in mortality, but importantly, it showed a significantly higher incidence of serious morbidity in the preoperative drainage group with a rate ratio (RaR) of 1.66 (95% CI 1.28–2.16;P = 0.002). There was no difference in length of hospital stay and not enough data reported for analysis of cost or quality of life.
“Based on the available level 1 data, the authors concluded that there was no evidence to support or refute routine preoperative biliary drainage in patients with obstructive jaundice.“
However, this review also underscored the fact that preoperative biliary drainage may be associated with an increased rate of adverse events and thus questioned the safety of this practice. This Cochrane review included old studies that evaluated patients undergoing percutaneous drainage, a technique used less frequently today for periampullary malignancies. Furthermore, several of these trials included patients with hilar and other types of biliary obstruction. However, the concept of preoperative decompression, as well as its purported benefits and observed results, may be reasonably extrapolated to patients with periampullary lesions.
First described by Pablo Mirizzi in 1948 as “functional hepatic syndrome”, Mirizzi’s syndrome was initially thought to be the result of a “physiologic sphincter” of the hepatic duct. It is now understood to be a result of mechanical obstruction of the common hepatic duct secondary to an impacted stone in the gallbladder neck, Hartmann’s pouch, or the cystic duct. The syndrome is very uncommon in Western populations with a reported prevalence of 0.05%-5.7% in large modern series of patients undergoing biliary surgery. With chronic stone impaction, inflammation and recurrent cholangitis can develop with subsequent erosion into the common bile duct (CBD) and resultant biliobiliary fistula between the gallbladder and CBD.
The syndrome encompasses a spectrum of disease. Broadly speaking, Mirizzi’s syndrome can be grouped into two major categories: (1) external compression of the CBD without a fistula (Type 1), and (2) erosion into the CBD causing a cholecystobiliary fistula (Type II-IV). Csendes classification is currently being used to reflect the above classification. Retrospective studies have identified an association between Mirizzi’s syndrome and gallbladder cancer, with an incidence as high as 28%, relative to an incidence of 1-2% in patients with uncomplicated gallstone disease. As with other malignant processes of the biliary tract, biliary stasis and chronic inflammation have been suggested to play a role. In general, it is difficult to distinguish benign Mirizzi’s syndrome from a neoplastic process preoperatively, although older patient age, significantly elevated Ca 19-9, and imaging features suggestive of invasion into the liver or a mass filling the gallbladder should raise suspicion for malignancy.
The most common presenting symptoms are right upper quadrant pain, jaundice, nausea/vomiting, and fever. This spectrum of findings overlaps with several other pathologic processes of the hepatobiliary tract, making preoperative diagnosis difficult. Additionally, the clinical picture may be complicated by the concurrent presence of acute cholecystitis, pancreatitis, or even gallstone ileus. Mirizzi’s syndrome should be suspected in any patient presenting with right upper quadrant pain and abnormal liver enzymes (particularly elevated bilirubin and alkaline phosphatase) or imaging suggestive of an impacted stone. Three findings on imaging together suggest a diagnosis of Mirizzi’s: 1) dilation of the biliary system above the level of the gallbladder neck, 2) the presence of a stone impacted in the gallbladder neck, and 3) an abrupt change to a normal width of the common duct below the level of the stone. Such findings should prompt further imaging to better define the biliary tree, either indirectly though magnetic resonance cholangiopancreatography (MRCP), or directly through endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC). No imaging modality is entirely sensitive for Mirizzi’s syndrome and the key is to maintain a high index of suspicion.
Management of Mirizzi’s syndrome depends on the degree of fistula. In Type I disease, laparoscopic cholecystectomy is usually achievable, either total (classic) or subtotal, depending on the specific intraoperative findings. If the view of safety can be attained with the critical structures isolated, a classic cholecystectomy may be performed. If the view of safety cannot be achieved due to inflammation or adhesions, the gallbladder is taken down retrograde and opened near the cystic duct orifice. All stones are removed, including any impacted stones, and the cystic duct orifice is examined for the presence of bile to determine whether it is patent. If the cystic duct is patent, it should be ligated (if possible), or the remnant gallbladder should be sutured closed over it (choledochoplasty). An external closed suction drain may be left in the gallbladder fossa and removed the following day if drainage is non-bilious. More commonly, the cystic duct is obliterated, and a subtotal cholecystectomy with removal of all stones is sufficient.
Management of Mirizzi’s syndrome in the presence of a biliobiliary fistula is more complex. If the fistula involves <1/3 of the CBD circumference (Type II), options include primary repair using absorbable suture, closure over a T-tube, or choledochoplasty using the remnant gallbladder. The last approach is preferable to maintain the diameter of the CBD and minimize the risk of subsequent stricture but requires that sufficient gallbladder remnant be available to allow closure. In the presence of a more extensive fistula (Type III or IV), bilioenteric anastomosis is usually the best option.
Transplantation for nonalcoholic steatohepatitis
The global obesity epidemic has dramatically increased the prevalence of NAFLD and made it the leading cause of chronic liver disease in Western nations. NAFLD is considered the hepatic manifestation of the metabolic syndrome and shares a strong association with type 2 diabetes mellitus, obstructive sleep apnea (OSA), and cardiovascular disease. Although cardiovascular disease is the leading cause of death in patients with NAFLD, the subset of patients who meet histopathologic criteria for NASH are those at greatest risk of liver-related morbidity and mortality. Ludwig and colleagues coined the term NASH in 1980 to describe a cohort of middle-aged patients with elevated serum liver enzyme levels who had evidence of alcohol-associated hepatitis on biopsy specimens in the absence of alcohol consumption. Subsequent study led to the proposed “2-hit” hypothesis in which a sequential progression from isolated fatty liver (IFL) to NASH involved the initial “hit” of hepatic steatosis followed by a second “hit” of oxidative stress resulting in liver injury. It was subsequently recognized that patients who have steatohepatitis on a liver biopsy specimen are at greatest risk for progression to cirrhosis compared with those who have IFL. Correspondingly, our understanding of the pathogenesis of NAFLD has evolved from the 2-hit hypothesis. NASH is expected to become the most common cause of cirrhosis and the leading indication for LT in the USA in the 2020s. As a major public health concern, an understanding of its epidemiology and pathogenesis is paramount to facilitate our ability to effectively diagnose and treat patients with NAFLD and NASH.
NAFLD is an increasingly frequent cause of cirrhosis and HCC. In fact, a report published in 2018 listed NAFLD as the second leading non-neoplastic indication for LT in adults in the USA, following alcohol-associated liver disease. Obesity (BMI ≥30 kg/m2) and type 2 diabetes mellitus are commonly encountered in patients with NAFLD; these 2 diseases have been recognized as risk factors for HCC, irrespective of the presence or etiology of cirrhosis. Although BMI is not necessarily a reliable indicator of adiposity in patients with end-stage liver disease, particularly in those with fluid retention and ascites, it is commonly used by many LT centers during the patient selection process. Morbid obesity (BMI ≥40 kg/m2 without significant obesity-related comorbidities or BMI ≥35 kg/m2 associated with obesity-related comorbidities) is commonly regarded as a relative contraindication to LT; however, data from the Organ Procurement and Transplantation Network demonstrate that 16.5% and 5% of patients who underwent LT in 2016 had a BMI greater than or equal to 35 kg/m2 and greater than or equal to 40 kg/m2, respectively.
NAFLD and Liver Transplantation
Analysis of data from the UNOS registry has suggested that the risk of primary graft nonfunction is increased and short- and long-term survival is poorer in morbidly obese liver transplant recipients with various causes of end-stage liver disease. However, when analyzed as an entire cohort and not stratified by BMI, patients with NAFLD have patient and graft survival rates that are comparable to those for other indications for LT. Many of the key precipitants of NAFLD (obesity, hyperlipidemia, and insulin resistance) are exacerbated by immunosuppression. Recurrence of NAFLD after LT causes graft injury, although graft loss does not typically occur. De novo NAFLD after LT has also been described. In the absence of specific therapy for NAFLD, therapeutic efforts after LT should center on weight control, optimal diabetic management, and use of a lipid-lowering agent, if indicated. Intensive noninvasive weight loss interventions pre-LT appear to be successful (reduction of BMI to <35 kg/m2) in a large proportion of patients (84%) enrolled in carefully monitored multidisciplinary protocols; however, 60% of patients regained weight to a BMI ≥35 kg/m2 post-LT. Although bariatric surgery is feasible in selected patients with NAFLD, this intervention is typically reserved for patients with early stages of liver disease and, as is the case for many other abdominal surgical procedures, is contraindicated in those with decompensated cirrhosis because of high morbidity and mortality. A strategy of combining LT with sleeve gastrectomy during the same operation has only been evaluated in small prospective series. The mean surgical time was not significantly different between LT and combined LT/sleeve gastrectomy, and the mean BMI reduction with the combined surgical approach was 20 kg/m2. Metabolic complications, such as post-transplant diabetes mellitus, as well as steatosis of the graft noted by US were significantly less frequent in patients undergoing LT/sleeve gastrectomy compared with patients who lost weight noninvasively pre-LT. The safety and efficacy of this combined surgical approach and other combinations of less invasive weight loss interventions, such as endoscopic techniques, pre-LT must be confirmed by large prospective studies before they can be recommended. Bariatric interventions are still an option post-LT; however, the procedure should be performed by an experienced surgeon, and the role of less invasive endoscopic techniques postLT is still under investigation.
Sleeve Gastrectomy vs NAFLD
Bariatric surgery leads to substantial weight loss that results in improved metabolic parameters and hepatic histology in patients with NAFLD, according to numerous large retrospective and prospective cohort studies. In one study of 109 patients with NASH who underwent follow-up liver biopsy one year after bariatric surgery, 85% of patients had resolution of NASH, and 33% had improvement in fibrosis. Initial concerns that fibrosis would worsen with rapid weight loss were unfounded, as demonstrated in a meta-analysis in which fibrosis improved by 11.9% from baseline after bariatric surgery. Although bariatric surgery is not recommended as a treatment for NASH, the abundant positive data in its favor suggest that surgical weight loss is a viable option for patients with comorbid conditions that would warrant the surgery for other reasons. Patients with NASH cirrhosis are at potentially higher risk for surgical complications, although some centers have demonstrated encouraging results with sleeve gastrectomy in patients with Child-Pugh class A cirrhosis.
BASICS OF SURGICAL TECHNIQUE
This e-book was designed to assist in learning related to experimental surgical technique, during the training of health professionals. Concisely and objectively, it presents the basic principles for professional practice in surgery and in basic techniques of the most relevant surgical procedures. It is directed to the training of general practitioners, through the technical base, illustrated in procedures described step by step, with reference to the routines of the discipline of Surgical Technique, at the Federal University of Maranhão. It is not a work aimed at surgical clinic nor does it presuppose a descriptive detail that definitively supplies the necessary information for the execution of procedures in patients. This book is specially dedicated to undergraduate students, to serve as a guide during the Experimental Surgical Technique. It was designed and structured in order to facilitate theoretical study and encourage practical learning. Assisting your training, we seek professionals better prepared for health care.
Laparoscopic Liver Resection
Laparoscopic hepatic resection is an emerging option in the field of hepatic surgery. With almost 3000 laparoscopic hepatic resections reported in the literature for benign and malignant tumors, with a combined mortality of 0.3% and morbidity of 10.5%, there will be an increasing demand for minimally invasive liver surgery. Multiple series have been published on laparoscopic liver resections; however, no randomized controlled trial has been reported that compares laparoscopic with open liver resection. Large series, meta-analyses, and reviews have thus far attested to the feasibility and safety of minimally invasive hepatic surgery for benign and malignant lesions.
The conversion rate from a laparoscopic approach to an open procedure was 4.1%. The most common type of laparoscopic liver resection performed is a wedge resection or segmentectomy (45%), followed by left lateral sectionectomy (20%). Major anatomic hepatectomies are still less frequently performed: right hepatectomy (9%) and left hepatectomy (7%). Cumulative morbidity and mortality was 10.5% and 0.3%.
BENEFITS OF LAPAROSCOPIC APPROACH
More importantly, almost all the studies comparing laparoscopic with open liver resection consistently showed a significant earlier discharge to home after laparoscopic liver resection. Lengths of stay were variable based on the country of origin of the studies but were consistently shorter for laparoscopic liver resection. Three studies published in the United States presented a length of stay of 1.9 to 4.0 days after laparoscopic liver resection. Studies from Europe showed an average length of stay of 3.5 to 10 days whereas those from Asia reported an average of length of stay of 4 to 20 days after laparoscopic liver resection.
Vanounou and colleagues used deviation-based cost modeling to compare the costs of laparoscopic with open left lateral sectionectomy at the University of Pittsburgh Medical Center. They compared 29 laparoscopic with 40 open cases and showed that patients who underwent the laparoscopic approach faired more favorably with a shorter length of stay (3 vs 5 days, P<.0001), significantly less postoperative morbidity (P 5 .001), and a weighted-average median cost savings of $1527 to $2939 per patient compared with patients who underwent open left lateral sectionectomy.
Initial concerns about the adequacy of surgical margins and possible tumor seeding prevented the widespread adoption of laparoscopic resection approaches for liver cancers. In comparison studies, there were no differences in margin-free resections between laparoscopic and open liver resection. In addition, no incidence of port-site recurrence or tumor seeding has been reported. With more than 3000 cases of minimally invasive hepatic resection reported in the literature (and no documentation of any significant port-site or peritoneal seeding), the authors conclude that this concern should not prevent surgeons from accepting a laparoscopic approach.
There were no significant differences in overall survival in the 13 studies that compared laparoscopic liver resection with open liver resection for cancer. For example, Cai and colleagues showed that the 1-, 3-, and 5-year survival rates after laparoscopic resection of HCC were 95.4%, 67.5%, and 56.2% versus 100%, 73.8%, and 53.8% for open resection. For resection of colorectal cancer liver metastasis, Ito and colleagues showed a 3-year survival of 72% after laparoscopic liver resection and 56% after open liver resection whereas Castaing and colleagues51 showed a 5-year survival of 64% after laparoscopic liver resection versus 56% after open liver resection.
Compared with open liver resections, laparoscopic liver resections are associated with less blood loss, less pain medication requirement, and shorter length of hospital stay. A randomized controlled clinical trial is the best method to compare laparoscopic with open liver resection; however, such a trial may be difficult to conduct because patients are unlikely to subject themselves to an open procedure when a minimally invasive approach has been shown feasible and safe in experienced hands. In addition, many patients would have to be accrued to detect a difference in complications that occur infrequently. Short of a large randomized clinical trial, meta-analysis and matched comparisons provide the next best option to compare laparoscopic with open liver resection. For laparoscopic resection of HCC or colorectal cancer metastases, there has been no difference in 5-year overall survival compared with open hepatic resection. In addition, from a financial standpoint, the minimally invasive approach to liver resection may be associated with higher operating room costs; however, the total hospital costs were offset or improved due to the associated shorter length of hospital stay with the minimally invasive approach.
Medically-Necessary, Time Sensitive: (MeNTS) Score
Operating During The COVID-19 Coronavirus Pandemic
“At the University of Chicago, members of the Department of Surgery decided to investigate this issue more precisely. As stay-at-home restrictions in some states are easing, and as non-emergency medical care is being reconsidered, how does one possibly triage the thousands upon thousands of patients whose surgeries were postponed? Instead of the term “elective,” the University of Chicago’s Department of Surgery chose the phrase “Medically-Necessary, Time Sensitive” (MeNTS). This concept can be utilized to better assess the acuity and safety when determining which patients can get to the operating room in as high benefit/low risk manner as possible. And unlike in any recent time in history, risks to healthcare staff as well as risks to the patient from healthcare staff, are now thrown into the equation. The work was published in the April issue of the Journal of the American College of Surgeons.
On March 17, 2020, the American College of Surgeons recommended that all “elective” surgeries be canceled indefinitely. These guidelines were published, stating that only patients with “high acuity” surgical issues, which would include aggressive cancers and severely symptomatic disease, should proceed. Based on the Elective Surgery Acuity Scale (ESAS), most hospitals were strongly encouraged to cancel any surgery that was not high acuity, including slow-growing cancers, orthopedic and spine surgeries, airway surgeries, and any other surgeries for non-cancerous tumors. Heart surgeries for stable cardiac issues were also put on hold. Patients and surgeons waited. Some patients did, indeed undergo non-Covid-19-related surgeries. But most did not. Redeployment is gradually turning to re-entry.
The re-entry process for non-urgent (yet necessary) surgeries is a complicated one. Decisions and timing, based on a given hospital’s number and severity of Covid-19 patients, combined with a given city or state’s current and projected number of Covid-19 cases, how sick those patients will be, and whether or not a second surge may come, involves a fair amount of guesswork. As we have all seen, data manipulation has become a daily sparring match in many arenas. The authors of the study created an objective surgical risk scoring system, in order to help hospitals across this country, as well as others across the world, better identify appropriate timing regarding which surgeries can go ahead sooner rather than later, and why. They factored several variables into their equation, to account for the multiple potential barriers to care, including health and safety of hospital personnel. They created scoring systems based on three factors: Procedure, Disease and Patient Issues.
CALCULATE MeNTS SCORE HERE
The authors of the study created an objective surgical risk scoring system, in order to help hospitals across this country, as well as others across the world, better identify appropriate timing regarding which surgeries can go ahead sooner rather than later, and why. They factored several variables into their equation, to account for the multiple potential barriers to care, including health and safety of hospital personnel. Each patient would receive an overall conglomerate score, based on all of these factors, with the lower risks giving them more favorable scores to proceed with surgery soon, and the higher risks giving patients a higher score, or higher risk regarding proceeding with surgery, meaning it may be safest, for now, to wait.
Dr. Jeffrey Matthews, senior author of the paper, and Department Chair at the University of Chicago, stated that this model is reproducible across hospital systems, in urban, rural, and academic settings. And in the event of potential unpredictable surges of Covid-19 cases, the scoring system “helps prioritize cases not only from the procedure/disease standpoint but also from the pandemic standpoint with respect to available hospital resources such as PPE, blood, ICU beds, and [regular hospital] beds.”
The scoring system is extremely new, and the coming weeks will reveal how patients, surgeons and hospitals are faring as patients without life-and-death emergencies and/or Covid-19 complications gradually begin filling the operating rooms and hospital beds. In addition, and perhaps just as important, the study authors note that creating systems whereby healthcare resources, safety, and impact on outcomes need to be considered more carefully for each patient intervention, the larger impact of each intervention on public health will be better understood: not only for today’s pandemic, but also in future, as yet unknown, global events.”
Source: Nina Shapiro, 2020
Discover our surgical video channel and lectures associated with the surgeon blog.
Share and Join: https://linktr.ee/TheSurgeon
Covid-19 and Digestive Surgery
The current world Covid-19 pandemic has been the most discussed topic in the media and scientific journals. Fear, uncertainty, and lack of knowledge about the disease may be the significant factors that justify such reality. It has been known that the disease presents with a rapidly spreading, it is significantly more severe among the elderly, and it has a substantial global socioeconomic impact. Besides the challenges associated with the unknown, there are other factors, such as the deluge of information. In this regard, the high number of scientific publications, encompassing in vitro, case studies, observational and randomized clinical studies, and even systematic reviews add up to the uncertainty. Such a situation is even worse when considering that most healthcare professionals lack adequate knowledge to critically appraise the scientific method, something that has been previously addressed by some authors. Therefore, it is of utmost importance that expert societies supported by data provided by the World Health Organization and the National Health Department take the lead in spreading trustworthy and reliable information.
Discover our surgical video channel and lectures associated with the surgeon blog.
Share and Join: https://linktr.ee/TheSurgeon
#Medicine #Surgery #GeneralSurgery #DigestiveSurgery
The operative conduct of the biliary-enteric anastomosis centers around three technical steps: 1) identification of healthy bile duct mucosa proximal to the site of obstruction; 2) preparation of a segment of alimentary tract, most often a Roux-en-Y jejunal limb; and 3) construction of a direct mucosa-to-mucosa anastomosis between these two. Selection of the proper anastomosis is dictated by the indication for biliary decompression and the anatomic location of the biliary obstruction. A right subcostal incision with or without an upper midline extension or left subcostal extension provides adequate exposure for construction of the biliary-enteric anastomosis. Use of retractors capable of upward elevation and cephalad retraction of the costal edges are quite valuable for optimizing visual exposure of the relevant hilar anatomy.
Division of the ligamentum teres and mobilization of the falciform ligament off the anterior surface of the liver also facilitate operative exposure; anterocephalad retraction of the ligamentum teres and division of the bridge of tissue overlying the umbilical fissure are critical for optimal visualization of the vascular inflow and biliary drainage of segments II, III, and IV. Cholecystectomy also exposes the cystic plate, which runs in continuity with the hilar plate. Lowering of the hilar plate permits exposure of the left hepatic duct as it courses along the base of segment IVb. In cases of unilateral hepatic atrophy as a result of long-standing biliary obstruction or preoperative portal vein embolization, it is critical to understand that the normal anatomic relationships of the portal structures are altered. In the more common circumstance of right-sided atrophy, the portal and hilar structures are rotated posteriorly and to the right; as a result, the portal vein, which is typically most posterior, is often encountered first; meticulous dissection is necessary to identify the common bile duct and hepatic duct deep within the porta hepatis.
BILIARY-ENTERIC ANASTOMOSIS_THECNICAL ASPECTS